Navigation Links
Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease
Date:5/23/2013

0 Program
PDE10 is an enzyme that is expressed in areas of the brain linked to diseases that affect cognition and psychomotor functions, including Huntington's disease and schizophrenia. Huntington's disease is a hereditary neurodegenerative disorder that leads to movement, cognition, and behavioral abnormalities and premature death. Cognitive dysfunction is responsible for substantial disability in these diseases and is not improved by current medications. Omeros' proprietary compound OMS824 inhibits PDE10 and is being developed for the treatment of cognitive disorders. In addition to potential benefits on cognition, OMS824 could also improve psychiatric manifestations, such as the positive (e.g., hallucinations) and negative (e.g., flat affect) symptoms of schizophrenia.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-Looking Statements
This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statemen
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
2. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
3. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
4. AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
5. AbbVies Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
6. Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated Patients with Gram-negative Pneumonia
7. Bayers Investigational Riociguat Granted U.S. FDA Priority Review for Pulmonary Arterial Hypertension and Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
8. Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013
9. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
10. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
11. Genocea Publishes Preclinical Data For Investigational Vaccine Candidate For HSV-2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014  Lockton Dunning ... of Lockton Companies, announced the addition of Vice ... will join Lockton Dunning,s Pharmacy Consulting team, Excelsior ... of relevant industry experience to the position.  Most ... Market Sales at Diplomat Specialty Pharmacy, where she ...
(Date:12/24/2014)... N.C. , Dec. 23, 2014  Medical Science ... As the key link between the medical device industry ... even more in the coming years as the device ... According to research by benchmarking firm, Best ... can gain an important edge is by harnessing new ...
(Date:12/22/2014)... 22, 2014   TRU-D SmartUVC LLC, producers ... robot, announced today that the General Services Administration has ... 2019.   This newly formed agreement will ... of government purchasers, including Department of Veteran Affairs and ... Security contacts purchasing solutions for the Ebola effort in ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2Role of Medical Science Liaisons Evolving in Medical Device Sector 2TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
(Date:12/24/2014)... (PRWEB) December 25, 2014 Epigenetics finds ... science research, including oncology, drug discovery, developmental biology, and ... emerging as one of the most widely used techniques ... to GLOBOCAN, the prevalence of cancer is rapidly growing ... cases, 8.2 million cancer deaths, and 32.6 million people ...
(Date:12/24/2014)... York, New York (PRWEB) December 24, 2014 ... to mount in a mass tort litigation currently underway ... LLP reports. As of December 24, 2014, court ... the proceeding on behalf of individuals who developed gynecomastia ... its use. Data from the Court indicates that this ...
(Date:12/24/2014)... New York (PRWEB) December 24, 2014 ... http://www.xareltolawsuit2015.com/ ) that allege the blood thinner caused ... has outlined a leadership structure for the proceeding, ... dated December 17th, the Court plans to select ... parties and also plans on appointing a Plaintiffs’ ...
(Date:12/24/2014)... TX (PRWEB) December 25, 2014 The ... to 2023” focuses on the current treatment landscape, unmet ... cancer market. Stivarga is a drug which is used ... drug is orally administered and is also prescribed to ... drug which is FDA approved is a multi-kinase inhibitor ...
(Date:12/24/2014)... Dennis Thompson HealthDay Reporter ... who have abstained from sex for one year will be allowed ... policy that would reverse a 31-year ban on donations from men ... Administration announced Tuesday its intention to release a new draft guidance ... donations from gay men. The FDA is changing its policy ...
Breaking Medicine News(10 mins):Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3
... , Diabetes: A Deeper Look ... , DETROIT, Dec. 3 In the United States, a ... the Detroit Science Center will debut its newest exhibit, Diabetes: A ... about diabetes, diabetes treatment and the role insulin plays in the body. ...
... , WASHINGTON, Dec. 3 The Redwood Gazette ... struggling financially and worried about paying for their medicines. The ... more than 6 million patients find programs providing prescription medicines for ... has access to information on more than 475 patient assistance programs, ...
... in solid organ transplants have been issued with expert advice ... the global H1N1 (swine flu) pandemic. The paper, ... also urges them to stay alert to the significant concerns ... even bird flu (H5N1), to develop into a strain with ...
... compulsive users also feel depressed or anxious when not online ... Chinese adolescents found that teens who are addicted to the ... teens. , The survey of 1,618 students aged 13 ... Guangzhou in Guandong Province found that about 16 percent said ...
... ... of surgical cases on the iPhone or iPod touch. Pop up menu’s and one touch exporting ... provider. , ... I-Surgery , a new iPhone application for surgery, can be used by surgeons, residents, surgical ...
... ... to cheer up children during the holidays with his self-published and illustrated books, “Little ... nationwide. , ... (PRWEB) December 3, 2009 -- Carlton Scott RN , hopes to bring holiday ...
Cached Medicine News:Health News:Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center 2Health News:Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center 3Health News:Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center 4Health News:Transplant infectious disease experts provide pandemic guidance 2Health News:Transplant infectious disease experts provide pandemic guidance 3Health News:Teen Internet Addicts More Likely to Self-Harm: Study 2Health News:Traveling Nurse Cheers up Kids with Handmade Books 2Health News:Traveling Nurse Cheers up Kids with Handmade Books 3
... parafollicular C-cells of the thyroid gland and ... action of calcitonin is to lower plasma ... in decreased mobilization of calcium from bone ... conditions associated with high levels of bone ...
... The HeartMate II Left Ventricular Assist System ... pump shown to restore hemodynamic function and ... Through the rotary action of a single-moving ... long-term full circulatory support by pumping blood ...
... the first, easy-to-use, non-invasive diagnostic technology ... cardiac dysfunction including acute heart failure, ... cardiac conditions. Designed to seamlessly fit ... enable clinicians caring for cardiac patients ...
... provides a new screening, diagnostic, treatment assessment ... management of sleep-related breathing disorders. The Watch-PAT ... need for an ambulatory, reliable, patient friendly ... the great number of OSA sufferers, and ...
Medicine Products: